Brookline Capital analyst Kumaraguru Raja initiates coverage on Biomea Fusion (NASDAQ:BMEA) with

Biomea Fusion stock falls after ending a public securities offering and revising clinical data timel

Gainers Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regula

Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ:BMEA), a clinical-stage diab

Worthington Enterprises surged 15.9% premarket after beating Q1 EPS and sales estimates; Wheeler REI

Biomea Fusion shares fall nearly 19% after hours, highlighting volatility in BMEA after Tuesday'

Gainers Jaguar Health (NASDAQ:JAGX) shares moved upwards by 32.2% to $45.56 during Tuesday's af

Shares of Biomea Fusion are trading sharply higher on Monday following an operational milestone for

Gainers Innovative Eyewear (NASDAQ:LUCY) stock rose 63.6% to $1.12 during Monday's regular sess

Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.12) per share which beat the analyst co

Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preserv

Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on P

Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.17) per share which beat the analyst co

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Cit

Citizens analyst Jonathan Wolleben initiates coverage on Biomea Fusion (NASDAQ:BMEA) with a Marke

A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years

Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:B

Citigroup analyst Yigal Nochomovitz maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and raises t

Biomea Fusion (NASDAQ: BMEA) shares rose Friday after the company reported positive Phase II data fo

D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and maint

Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or "the Company") (Nasdaq: BM

Citigroup analyst Yigal Nochomovitz maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and lowers t

D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and lower

Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or the "Company") (Nasdaq: BM

Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.27) per share which missed the analyst

D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and maint

Biomea Fusion reported favorable safety for icovamenib in a 52-week diabetes study, alongside a $25

Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company,

Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company,

Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in t

D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and maint

Jefferies analyst Roger Song initiates coverage on Biomea Fusion (NASDAQ:BMEA) with a Buy rating

Citigroup analyst Yigal Nochomovitz maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and lowers t

Scotiabank analyst George Farmer maintains Biomea Fusion (NASDAQ:BMEA) with a Sector Outperform a

D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and maint

Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.51) per share which beat the analyst co

D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and maint

Citigroup analyst Yigal Nochomovitz maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and lowers t

D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and maint

In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide prom

D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and maint